Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting ...

Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

In the Boston area, three months into the new year, the mood in the biotech industry has soured and the outlook has clouded.

Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

Leerink Partners 2025 Global Healthcare Conference Call March 11, 2025 8:00 AM ET. Company Participants. Ryan Crowe - SVP, IR & Strat ...

In a report released today, Daina Graybosch from Leerink Partners downgraded 2seventy bio (TSVT – Research Report) to a Hold, with a price ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Leerink downgraded 2seventy Bio (TSVT) (TVST) to Market Perform from Outperform with a price target of $5, down from $9, to reflect the pending ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Fintel reports that on March 7, 2025, Leerink Partners initiated coverage of CorMedix (NasdaqGM:CRMD) with a Outperform ...

Stock analysts at Leerink Partners started coverage on shares of CorMedix (NASDAQ:CRMD – Get Free Report) in a report ...